Samsung Biologics Co.,Ltd. (207940.KS)

803.000,00 -7.000,00 (-0,86%) Börsenschluss: 03:30PM KST

Samsung Biologics Co.,Ltd.

300, Songdobio-daero
Yeonsu-gu
Incheon 21987
South Korea
82 3 2455 3114
https://samsungbiologics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John Chongbo Rim	CEO, President & Chairman of Board	3,12B	N/A	1961
Mr. Dong-Joong Kim	CFO, Executive VP, MD & Director	666M	N/A	1965
Mr. Pierre Catignol	Executive VP & Head of Operation Center	N/A	N/A	1968
Dr. Namjin Chung Ph.D.	Executive VP and Head of Bio R&D Centre & CSO	N/A	N/A	N/A
Mr. James J. Choi	Executive VP, Head of CDO Development Center & Head of Sales Center	569M	N/A	1967
Mr. Kyuho Lee	Executive VP, Head of People Center, & Chief Human Resource Officer	N/A	N/A	N/A
Dr. Brian Hosung Min Ph.D.	Executive VP & Head of CDO Development Center	N/A	N/A	N/A
Mr. Doyoung Heo	Vice President & Head of Finance	N/A	N/A	1975
Mr. Heekyun Lim	VP & Head of Business Consulting Team	N/A	N/A	1975
Dr. Kun Lo Ph.D.	Executive VP, Head of EPCV Center & Director	N/A	N/A	1963

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in KRW.

Beschreibung

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Corporate Governance

Samsung Biologics Co.,Ltd.s ISS Governance QualityScore, Stand 1. Juli 2024, lautet 4. Die grundlegenden Scores sind Audit: 1, Vorstand: 4, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.